Session Speakers:

From Discovery to Preclinical: Evaluating Liabilities of a Rare PTM in a Bispecific ADC

Shlomo Zarzhitsky, Bristol-Myers Squibb Company

Integrated Experimental and Computational Workflow Enabled by In-Source Reduction for “Truly Complete” Disulfide Mapping

Yongsheng Xiao, Wuxi Biologics

Artificial Oxidation: A Major Challenge for MAM Implementation and Long-Term QC Testing of Therapeutic Proteins

Dylan Riggs, Amgen Inc.

LC-MS Workflow for Characterization and Stability Assessment of VHH-Fc-siRNA Conjugates

Magali Godard, Institut des Biomolécules Max Mousseron (IBMM)

Dylan Riggs